Propranolol plus immunotherapy and chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB-IV) non-small cell lung cancer that cannot be removed with surgery
- You have not had chemotherapy or immunotherapy for advanced disease before (prior treatment before the cancer spread is okay if it ended at least a year ago)
- Your cancer does not have specific gene changes (EGFR, ALK, or ROS1) – your doctor can check this from a biopsy
- You are able to take a beta-blocker (propranolol) – this means you don't have asthma, very slow heart rate, certain heart problems, or severe diabetes
- You have at least one tumor that can be measured on a CT scan or MRI, and your blood counts, liver, and kidney function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This trial tests whether adding a blood-pressure medicine (propranolol) to a combination of two immunotherapy drugs plus chemotherapy is safe and works better for locally advanced colon cancer that has not spread. It's for tumors that are pMMR/MSS, which are less likely to respond to immunotherapy alone, so the propranolol may help the immune system fight the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.